Key result
Nimesulide exposure in high-risk pregnancies resulted in 88.6% (39 of 44) of women taking home a live baby, with reversible oligohydramnios occurring in 54% of cases.
Why the study?
Does nimesulide improve pregnancy outcomes and prevent preterm delivery in women at high risk of second trimester loss?
Observational (n=44)
Does nimesulide improve pregnancy outcomes and prevent preterm delivery in women at high risk of second trimester loss?
Nimesulide appears to offer significant benefit in preventing preterm delivery in high-risk women without long-term fetal harm, provided there is intensive ultrasound monitoring for reversible oligohydramnios.
Answers are grounded in this paper and cite their sources.
Supports monitored nimesulide use in high-risk pregnancies; leaves open randomized confirmation of benefit.
We report pregnancy outcome and fetal side effects in women at high risk of second trimester loss and early preterm delivery treated with nimesulide. This was a prospective observational study of 44 women treated with nimesulide from 17 to 32 weeks. All women underwent weekly ultrasound scans for AFI, Doppler studies of the ductus arteriosus and transvaginal assessment of cervical length. Outcome data were collected. Oligohydramnios occurred in 54% of cases; this returned to normal in all cases on discontinuation of treatment. There were no cases of constriction of the ductus arteriosus. Thirty-nine women took home a live baby. The mean gestation at delivery was 33 weeks and 1 day and the mean birth weight was 2105 g. Nimesulide appeared to have a significant benefit in women at high risk of preterm delivery with no long-term harmful effects on the fetus if monitored closely with an intensive ultrasound scanning regimen. Randomised placebo controlled trials are required to assess fully the benefit of COX-2 selective and specific prostaglandin synthesis inhibitors.
No takes yet. Share an insight, caveat, or question.
Sawdy et al. (2004) conducted an observational in high risk of second trimester loss and early preterm delivery (n=44). Nimesulide was evaluated on live baby. Nimesulide exposure in high-risk pregnancies resulted in 88.6% (39 of 44) of women taking home a live baby, with reversible oligohydramnios occurring in 54% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: